Could chemo keep uterine sarcoma at bay? new trial seeks answers
NCT ID NCT07076186
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 4 times
Summary
This Phase II trial is testing whether a combination of two chemotherapy drugs, doxorubicin and trabectedin, can help prevent uterine leiomyosarcoma from coming back after surgery. The study enrolls 48 patients with high-risk, early-stage disease who have had their tumor fully removed. Researchers will monitor side effects and how long patients remain cancer-free.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- doxorubicin and trabectedin chemotherapy
- What this could lead to
- If successful, this could provide a standard chemotherapy option to delay or prevent recurrence of uterine leiomyosarcoma after surgery.
- What could go wrong
- This is a small Phase II trial with only 48 participants, so results may not apply broadly. Chemotherapy side effects can be significant, and the treatment may not improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UTERINE LEIOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.